Quarterly report pursuant to Section 13 or 15(d)

Consolidated Balance Sheets

v3.7.0.1
Consolidated Balance Sheets - USD ($)
Jun. 30, 2017
Dec. 31, 2016
Current Assets    
Cash $ 436,086 $ 182,561
Trade accounts receivable, net 519,624 444,743
Other receivables 2,250
Product deposit 74,043
Inventory, net 127,448 160,270
Total Current Assets 1,157,201 789,824
Current Liabilities    
Accounts payable and accrued expenses 561,833 752,930
Derivative liabilities 955,014 192,254
Convertible notes payable 100,000
Notes payable, net of discount in 2016 74,043 106,365
Total Current Liabilities 1,590,890 1,151,549
Stockholders' Equity (Deficit)    
Common stock, $0.01 par value; 50,000,000 shares authorized, 40,995,763 and 35,570,157 shares issued, 40,657,963 and 35,245,157 outstanding as of June 30, 2017 and December 31, 2016, respectively 409,957 355,701
Additional paid-in capital 9,532,060 9,070,064
Accumulated (deficit) (10,001,198) (9,693,882)
Equity (59,181) (268,117)
Treasury stock, 337,800 and 325,000 shares, at cost (90,204) (87,053)
Total Immudyne, Inc. Stockholders' (Deficit) (149,385) (355,170)
Non-controlling interest (284,304) (6,555)
Total Stockholders' (Deficit) (433,689) (361,725)
Total Liabilities and Stockholders' (Deficit) $ 1,157,201 $ 789,824